Life Sciences Updates from Cooley LLPhttp://www.cooley.com The Centers for Medicare & Medicaid Services ("CMS") announced on May 3, 2012 that it will delay until at least January 1, 2013 commencement of data collection obligations for life sciences and other companies subject to the "sunshine" provisions in Section 6002 of the Patient Protection and Af...http://www.cooley.com/showalert.aspx?Show=66479Thu, 10 May 2012 00:00:00 GMTThere are many reasons for companies in the health care and life sciences industries to develop and maintain a strong compliance program. For executives at health care and life sciences companies, the Responsible Corporate Officer ("RCO") doctrine is an especially compelling reason. The RCO doctrine...http://www.cooley.com/showalert.aspx?Show=66382Wed, 18 Apr 2012 00:00:00 GMT On February 9, 2012, the Food and Drug Administration released three long-awaited "draft" industry Guidances concerning Biosimilars, also known as Follow on Biologics. The draft Guidance documents provide in broad strokes the FDA's proposal for its implementation of the Biologics Price Competition ...http://www.cooley.com/showalert.aspx?Show=66122Thu, 16 Feb 2012 00:00:00 GMTReston, Va. – January 26, 2012 – Amgen and Micromet, Inc. today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company with its research and development center in Munich and headquarters in Rockville, Md., for $11...http://www.cooley.com/showpressrelease.aspx?Show=66070Thu, 26 Jan 2012 00:00:00 GMTCooley is mentioned for representing Micromet in its $1.2 billion sale to Amgen.  The deal team was led by Christian Plaza, partner in Cooley's Life Sciences practice group and Barbara Borden, partner and chair of Cooley's Mergers and Acquisitions practice group.View the Reuters article here. ...http://www.cooley.com/showinthenews.aspx?Show=66087Thu, 26 Jan 2012 00:00:00 GMTA Cooley Alert authored by partner Drew Gantt and associate David Sclar, members of Cooley's Life Sciences practice group, was referenced in an article on the rule proposed recently by the Centers for Medicare and Medicaid requiring pharmaceutical companies to disclose payments to doctors.View the a...http://www.cooley.com/showinthenews.aspx?Show=66086Tue, 24 Jan 2012 00:00:00 GMTDavid Sclar, Washington, D.C.-based associate in Cooley's Life Sciences practice group, was quoted in two articles on the sunshine provisions of the Patient Protection and Accountable Care Act ("PPACA") enacted in 2010. View the articles here.http://www.cooley.com/showinthenews.aspx?Show=66435Mon, 23 Jan 2012 00:00:00 GMT On December 19, 2011, the Centers for Medicare and Medicaid ("CMS") published a proposed rule implementing the "sunshine provisions" in Section 6002 of the Patient Protection and Affordable Care Act ("PPACA"). These provisions require (i) applicable manufacturers to report annually to CMS certain p...http://www.cooley.com/showalert.aspx?Show=66048Fri, 20 Jan 2012 00:00:00 GMT Among other things, 2012 will be the year of the Department of Health and Human Services ("HHS") Office of Civil Rights ("OCR") pilot audit program to assess compliance with the Health Insurance Portability and Accountability Act ("HIPAA") Privacy and Security Rules and Breach Notification standard...http://www.cooley.com/showalert.aspx?Show=66038Wed, 18 Jan 2012 00:00:00 GMTBarbara Kosacz, partner and chair of Cooley's Life Sciences practice group, was interviewed about Reata Pharmaceutical's $400 million deal with Abbott.View the article here.http://www.cooley.com/showinthenews.aspx?Show=66013Tue, 13 Dec 2011 00:00:00 GMT